| |
 |
|
|
|
|
|
EPIDEMIOLOGY |
Differing
relationship by ethnicity between obesity and blood pressure
in children living in Australia
(Posted: 12/31 | View
Article)
Hyperinsulinaemia may account for
the association of overweight and clustering of cardiovascular
risk factors
in prediabetes
(Posted: 112/29 | View
Article)
Interaction between total testosterone
and estradiol during the menopausal transition as a predictor
of risk of
developing metabolic syndrome
(Posted: 12/26 | View
Article)
Secular trends in various lipid
abnormalities in an urban Indian population
(Posted: 12/24 | View
Article)
Relationships between metabolic syndrome or its
components and incident Alzheimer’s disease
or vascular dementia
(Posted: 12/22 | View
Article)
Relationship
between lipid and glucose levels in a large European population
without previous diabetes
(Posted: 12/16 | View
Article)
Small dense LDL cholesterol associated with severe coronary
artery disease
(Posted: 12/15 | View
Article)
Aminotransferase levels as a potential biomarker for
the risk of metabolic disease
(Posted: 12/12 | View
Article)
Polymorphisms in susceptibility genes for type 2 diabetes
and obesity predispose to the metabolic syndrome
(Posted: 12/08 | View
Article)
Following a Mediterranean-type diet shown to be inversely
associated with the clustering of cardiovascular risk factors
among high-risk patients
(Posted: 12/02 | View
Article) |
| |
PATHOPHYSIOLOGICAL
EFFECTS |
Strong
correlation between plasma endocannabinoid levels and high
plasma triacylglycerol and low HDL(3)-cholesterol
in viscerally obese men
(Posted: 12/30 | View
Article)
Differences in cardiovascular
risk factors among youths with type 2 diabetes and nondiabetic
controls
(Posted: 12/23| View
Article)
Insights into the systemic processes
influencing arteriolar and venular calibre
(Posted: 12/09 | View
Article)
Metabolic
syndrome linked to cataract formation in the Blue Mountains
Eye Study
(Posted: 12/05 | View
Article)
Traditional risk factors for coronary heart disease shown
to have an impact on vascular function in young people
(Posted: 12/04 | View
Article)
Depression as an important comorbidity of metabolic syndrome
in a general population
(Posted: 12/01 | View
Article) |
| |
METABOLIC
SYNDROME COMPONENTS / RISK FACTORS /
ASSOCIATED RISKS |
HIGH
BLOOD PRESSURE
Mild increase in body mass index
shown to be associated with prehypertension in a general
Japanese population
(Posted: 12/11 | View
Article) ABDOMINAL
OBESITY
Waist and extremity circumferences
shown to have opposite and independent effects on mortality
(Posted: 12/18 | View
Article)
|
| |
PROGNOSIS
/ OUTCOMES |
CARDIOVASCULAR DISEASE
Association
of metabolic syndrome and its components with all-cause and
cardiovascular mortality in a general Italian population
(Posted: 12/19 | View
Article)
Metabolic
syndrome as independent determinant of carotid intima-media
thickness in both sexes
(Posted: 12/03 | View
Article) |
| |
PREVENTION
AND TREATMENT |
Insulin
resistance and parental obesity as predictors of unresponsiveness
to standard therapeutic lifestyle change
intervention
(Posted: 12/10 | View
Article) |
 |
| |
CME:
Rosita Visit 1 - Metabolic Syndrome
|
| |
Topic:
|
|
Cardiology |
Relevant
Terms:
|
|
Cardiology, diabetes, endocrinology, nephrology,
ophthalmology, risk reduction |
Primary
Audience:
|
|
Primary Care Physicians, Cardiologists, Endocrinologists |
Launch
Date:
|
|
12-Sep-08 |
Credits:
|
|
0.5 AMA PRA Category 1 Credit(s)™ |
|
|
|
30-Sep-09 |
Faculty:
|
|
Course Chair: Frank
M. Sacks, MD
Consultant: Michel
P. Hermans, MD
Consultant: Melinda
D. Maryniuk, MEd, RD, CDE |
Registration:
|
|
Register | View
Additional Information |
|
LEARNING
OBJECTIVES
Upon successful
completion of this activity,
the clinician will be better able to:
- List the criteria used for diagnosing metabolic syndrome
- List the most current guidelines and describe the
available diagnostic tools used to assess metabolic
syndrome risk factors
- Develop a systematic risk factor reduction plan
for patients with diabetes, hypertension, dyslipidemia
and other metabolic syndrome criteria
- Apply various therapies to treat metabolic syndrome
and reduce risk factors in the context of primary and
secondary prevention
|
 |
| 5th
Asia Oceania Conference on Obesity |
Date:
|
February 5-8,
2009 |
Location:
|
Powai, Numbai |
Website:
|
http://www.aiaaro.com/aoco-conf.htm |
| |
| International
Stroke Conference 2009 |
Date:
|
February
17-20, 2009
|
Location:
|
San Diego,
CA, USA |
Website:
|
http://www.americanheart.org |
| |
| Advanced
Technologies & Treatments for Diabetes |
Date:
|
February 25-28,
2009 |
Location:
|
Athens, Greece |
Website:
|
http://www2.kenes.com/attd/Pages/home.aspx
|
| |
3rd
International Conference on Hypertension, Lipids,
Diabetes and Stroke Prevention
|
Date:
|
March 4-6,
2009 |
Location:
|
Berlin, German |
Website:
|
http://www2.kenes.com |
|
| Joint
Conference - 49th Cardiovascular Disease Epidemiology
and Prevention -and- Nutrition, Physical Activity
and Metabolism - 2009 |
Date:
|
March 10-14,
2009 |
Location:
|
Palm Harbor, FL, USA
|
Website:
|
http://www.americanheart.org |
| |
| 13th
Pan Arab Conference on Diabetes (PACD) |
Date:
|
March 24-27,
2009
|
Location:
|
Cairo, Egypt |
Website:
|
http://www.arab-diabetes.com/introduction.htm |
| |
| American
College of Cardiology -58th Annual Scientific Session |
Date:
|
March 29-31,
2009
|
Location:
|
Orlando,
FL, USA
|
Website:
|
http://acc09.acc.org/Pages/default.aspx |
| |
| 3rd International
Congress on Prediabetes and Metabolic Syndrome |
Date:
|
April 1-4,
2009 |
Location:
|
Nice, France |
Website:
|
http://www2.kenes.com |
 |
|
2009
ONGOING TRIALS
Hypoglycaemic
Agents
Record, NAVIGATOR, Heart2D, AdRem,
STARR
Lifestyle
and Obesity Management
SCOUT
Others
VITATOPS, SEARCH
Antihypertensive
Agents
VALISH, NAVIGATOR, AdRem, STARR
Lipid
Modifying Agents
AURORA, SEARCH
FEATURED LANDMARK STUDY OF
2008
Hypoglycaemic
Agents
STENO-2
(Observational
Follow-Up)
Effect of a multifactorial
intervention on mortality in type 2 diabetes
Outcome: Time to death
from any cause.
Number of participants: 160 patients (130 in the observational follow-up) with type
2 diabetes and microalbuminuria at entry.
Comparison: Intensive
vs standard treatment (intensive treatment: stepwise implementation
of behavioural modification, pharmacological therapy targeting
hyperglycaemia, hypertension, dyslipidemia, and microalbuminuria,
along with cardiovascular disease prevention with low-dose
aspirin). Mean treatment period of 7.8 years, followed by a
mean observational period of 5.5 years.
Design: Randomized, open,
parallel trial.
View
Abstract
|
Framingham
Risk Assessment Tool
Estimates 10-year risk of developing
hard CHD
> View
Tool
Procam Risk Calculator
Estimates your risk
of a heart attack (myocardial infarction) within the
next 10 years based upon data of the PROCAM Study
> View
Calculator
SCORE
(European High Risk Chart)
Estimates 10 year risk
of fatal CVD in high risk regions of Europe by gender, age, systolic
blood pressure, total cholesterol and smoking status.
> View
Chart
UKPDS Risk Engine
The UKPDS Risk
Engine is a type 2 diabetes specific risk calculator
based on 53,000 patients years of data from the UK Prospective
Diabetes Study, which also provides an approximate 'margin
of error' for each estimate.
> View
Risk Engine
|
Mission
of the Metabolic
Syndrome Institute |
Created
in 2003, the Metabolic Syndrome Institute is an independent
and not for profit association. Its members are international
experts in lipid metabolism, diabetes, heart disease,
endocrinology obesity, genetics, epidemiology, basic
research and health economics. Being the first association
totally devoted to the dissemination of knowledge about
the metabolic syndrome, the Metabolic Syndrome Institute
will provide an international multidisciplinary approach
to a worldwide public health problem.
|
|
